Despite some progress, Alzheimer's fight falling flat

Sunday, September 23, 2018

Print this page Email A Friend!

PARIS, France (AFP) — It's a devastating disease driving a dementia epidemic ruining tens of millions of lives, but with no new medical treatment since the turn of the century the fight against Alzheimer's is foundering.

Despite decades of research and hundreds of millions of dollars, the precise cause of the neurodegenerative disease — which leaves victims suffering from memory loss, disorientation and behavioural problems — remains poorly understood.

“It's a bit like solving a jigsaw puzzle without knowing what the end result needs to look like,” said Pierre Tariot, director of the Banner Alzheimer's Institute in Phoenix, Arizona.

This year alone, pharmaceutical giants — including Lundbeck, Takeda, Merck & Co, Janssen Biotech, AstraZeneca, and Eli Lilly — have either halted or failed in their search for a new Alzheimer's drug.

US drug giant Pfizer said in January it was abandoning all research into the disease.

The problem, according to Marie Sarazin, director of neurology at the Saint-Anne hospital in Paris, is that scientific research has followed “the same track” for decades.

After trials on mice focused on diseased neurons in the brain appeared to produce a breakthrough in the early 2000s, many corporations “thought they'd hit the jackpot”, Sarazin said.

But follow-up research has so far failed to produce a new medical treatment for Alzheimer's. Indeed, the long-held hypothesis over what causes the disease in the first place is now being reconsidered.

Astronomical cost

Alzheimer's occurs when neurons in the brain lose their ability to communicate with one another, leading patients to struggle to remember names and places, orientate themselves or interact with loved ones.

Worldwide, about seven per cent of people over 65 suffer from the disease or some form of dementia, a percentage that rises to 40 per cent above the age of 85.

The number afflicted is expected to triple by 2050 to 152 million, according to the World Health Organization, posing a huge challenge to health care systems.

Alzheimer's cost an estimated US$818 billion (700 billion euros) in 2015 — equivalent to around one per cent of global GDP, and this is predicted to double by 2030.

Last Friday is World Alzheimer's Day, an event launched in 2012 to raise global awareness of the disease.

It comes this year with a glimmer of promise for a breakthrough: a joint US-Japanese clinical trial of an antibody designed to breakdown proteins thought to hamper neuroactivity significantly helped the brain function of test subjects.

Last Wednesday, a team of scientists in the US said they had eliminated dead-but-toxic cells occurring naturally in the brains of mice designed to mimic Alzheimer's and slowed neuron damage and memory loss associated with the disease.

But with developed nations dealing with the health challenges posed by ageing populations, many experts agree that more attention must focus on prevention as well as cure.

Exercise, drinking less alcohol and eating a balanced diet have all shown to reduce the risk of developing Alzheimer's.

“It seems that like in any other neurodegenerative disease, the key will be to go into prevention, as early as possible before signs and symptoms of the pathology occurs,” Danny Bar-Zohar, global head of neuroscience development at Novartis, told AFP.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon